Invitae, which consolidates available genetic tests into a single service, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The San Francisco, CA-based company, which was founded in 2010 and booked $800,000 in sales for the 12 months ended September 30, 2014, plans to list on the NYSE under the symbol NVTA. Invitae initially filed confidentially on November 6, 2014. J.P. Morgan is the sole bookrunner on the deal. No pricing terms were disclosed.
